Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
17.56
-0.39 (-2.17%)
At close: Dec 5, 2025, 4:00 PM EST
17.22
-0.34 (-1.94%)
After-hours: Dec 5, 2025, 6:20 PM EST
Avalo Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Avalo Therapeutics stock have an average target of 30.14, with a low estimate of 15 and a high estimate of 48. The average target predicts an increase of 71.64% from the current stock price of 17.56.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 29, 2025.
Analyst Ratings
The average analyst rating for Avalo Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 6 | 6 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +127.79% | Sep 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $25 | Strong Buy | Maintains | $15 → $25 | +42.37% | Sep 17, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Aug 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | -14.58% | Jun 2, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +30.98% | Mar 25, 2025 |
Financial Forecast
Revenue This Year
n/a
from 441.00K
Revenue Next Year
n/a
EPS This Year
-5.82
from -20.91
EPS Next Year
-4.71
from -5.82
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.47 | -1.94 | ||||
| Avg | -5.82 | -4.71 | ||||
| Low | -7.28 | -7.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.